Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PRO-232 Ophthalmic Solution in Healthy Volunteers
NCT06352541Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in ocular infection and ocular inflammation comparing PRO-232 with Placebo (2 arms). Primary endpoints: Incidence of Unexpected Related Adverse Reactions at Day 12, Changes in intraocular pressure at Day 8 and 1 more. Started Feb 2024; status: completed.
02
Drugs
navtemadlin
03
Conditions
ocular infectionocular inflammation
Beyond the preview
Go deeper on NCT06352541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352541.